Inhibitors of glucose transport and glycolysis as novel anticancer therapeutics

Figure 1 Glycolysis and inhibitors/activators of glycolysis as potential anti-cancer therapeutics. Glucose transporters and enzymes are shown in red and glycolytic intermediates are shown in blue. Inhibitors/activators are in black squares. PPP: Pentose phosphate pathway; OXPHOS: Oxidative phosphorylation; shown in green. GLUTs: Glucose transporters; HK: Hexokinase; GPI: Glucose-6-phosphate isomerase; PFK: Phosphofructokinase; ALD: Aldolase; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; PGK: Phosphoglycerate kinase; PGAM1: Phosphoglycerate mutase 1; ENO: Elonase; PKM2: Pyruvate kinase M2; LDH: Lactate dehydrogenase; PDK: Pyruvate dehydrogenase kinase; PDH: Pyruvate dehydrogenase; G6PD: Glucose-6-phosphate dehydrogenase; TKTL1: Transketolase-like enzyme 1; PHGDH: Phosphoglycerate dehydrogenase; G6P: Glucose 6-phosphate; F6P: Fructose 6-phosphate; F-1,6-bisP: Fructose 1,6-bisphosphate; 3-PG: 3-phosphoglycerate; 2-PG: 2-phosphoglycerate; 6-P-gluconolactone: 6-phosphogluconolactone; Xylulose-5-P: D-xylulose-5-phosphate; 2-DG: 2-deoxyglucose; 3-BP: 3-bromopyruvate; 3PO: 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; DCA: Dichloroacetate; 6-AN: 6-aminonicotinamide.